United Therapeutics Corporation $UTHR Shares Sold by Assetmark Inc.

Assetmark Inc. reduced its position in United Therapeutics Corporation (NASDAQ:UTHR) by 9.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 645,908 shares of the biotechnology company’s stock after selling 69,926 shares during the period. Assetmark Inc. owned about 1.50% of United Therapeutics worth $270,771,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC increased its holdings in United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after acquiring an additional 364,713 shares in the last quarter. Invesco Ltd. increased its stake in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares during the last quarter. Norges Bank purchased a new position in shares of United Therapeutics during the 2nd quarter worth $136,453,000. Amundi raised its holdings in shares of United Therapeutics by 3.6% during the 2nd quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock worth $107,113,000 after acquiring an additional 12,633 shares during the period. Finally, First Trust Advisors LP grew its stake in shares of United Therapeutics by 2.5% in the 2nd quarter. First Trust Advisors LP now owns 305,512 shares of the biotechnology company’s stock valued at $87,789,000 after buying an additional 7,484 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $483.25, for a total value of $4,010,975.00. Following the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $17,774,418.25. This trade represents a 18.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Monday, February 9th. The shares were sold at an average price of $474.65, for a total transaction of $10,679,625.00. The SEC filing for this sale provides additional information. Insiders sold a total of 502,214 shares of company stock worth $242,241,993 over the last ninety days. 10.30% of the stock is owned by company insiders.

United Therapeutics Trading Up 0.1%

NASDAQ UTHR opened at $476.13 on Friday. The company has a market capitalization of $20.50 billion, a PE ratio of 18.04, a price-to-earnings-growth ratio of 2.53 and a beta of 0.85. The business’s 50-day moving average price is $486.33 and its 200 day moving average price is $431.32. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. HC Wainwright upped their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company increased their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Finally, UBS Group increased their target price on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.